|
|
|
| Clinical Efficacy of Budesonide, Glycopyrrolate, and Formoterol Fumarate Aerosol Combined with an Internet-of-Things Respiratory Rehabilitation Trainer in the Treatment of Patients with Moderate-to-Severe COPD |
| HUANG Haichen, XIA Qiang, HU Shasha |
| Department of Respiratory and Critical Care Medicine, Xinyang Central Hospital, Xinyang Henan 464000 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical efficacy of budesonide, glycopyrrolate, and formoterol fumarate aerosol combined with an internet-of-things (IoT) respiratory rehabilitation trainer in the treatment of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). 【Methods】 A total of 96 patients with stable moderate-to-severe COPD admitted to our hospital from July 2024 to June 2025 were selected and divided into a control group and an observation group using a random number table method, with 48 cases in each group. The control group was treated with budesonide, glycopyrrolate, and formoterol fumarate aerosol, while the observation group was additionally treated with an IoT respiratory rehabilitation trainer on the basis of the control group. The clinical efficacy, pulmonary function indicators [peak expiratory flow (PEF), forced expiratory volume in the first second/forced vital capacity (FEV1/FVC)], 6-minute walking distance (6MWD), and quality of life [St. George's Respiratory Questionnaire (SGRQ) score] were compared between the two groups. 【Results】 The total effective rate of the observation group was higher than that of the control group (P<0.05). After 8 weeks of treatment, the PEF and FEV1/FVC of both groups were higher than those before treatment, and the 6MWD was longer than that before treatment. Moreover, the PEF and FEV1/FVC of the observation group were higher than those of the control group, and the 6MWD was longer than that of the control group, with statistically significant differences (P<0.05). The symptom, activity, and impact scores of both groups were lower than those before treatment, and those of the observation group were lower than those of the control group, with statistically significant differences (P<0.05). 【Conclusion】 Budesonide, glycopyrrolate, and formoterol fumarate aerosol combined with an IoT respiratory rehabilitation trainer can further improve pulmonary function and exercise endurance in patients with moderate-to-severe COPD by strengthening respiratory muscle function and optimizing ventilation efficiency, reduce acute exacerbations, enhance quality of life, and demonstrate good safety, making it suitable for clinical promotion
|
|
Received: 17 October 2025
|
|
|
|
|
|
[1] 张天薇,李梦夏,范习康,等.慢性阻塞性肺疾病加重的流行病学研究进展[J].现代预防医学,2025,52(13):2343-2348.
[2] 陈丽君,刘美芳,张慧芳,等.银川市≥40岁人群慢性阻塞性肺疾病流行病学数据更新及启示[J].中华健康管理学杂志,2023,17(12):893-898.
[3] 姜爱雯,张瑞雪,赵学萍,等.布地格福吸入气雾剂治疗慢性阻塞性肺疾病患者的系统性评价[J].中国药物应用与监测,2025,22(1):185-188.
[4] 王鹏鹏,梁乐,李亚美.国家医保谈判政策对布地格福吸入气雾剂、格隆溴铵福莫特罗吸入气雾剂用于中重度慢性阻塞性肺疾病维持治疗经济性的影响[J].临床药物治疗杂志,2025,23(3):54-61.
[5] 李菲,陈伟伟,高蒙蒙,等.呼吸康复训练对老年慢性阻塞性肺疾病患者肺功能和免疫功能的影响[J].老年医学与保健,2024,30(4):998-1002.
[6] 邵靖雅,吉祥雨,王舒磐,等.肺康复训练对慢性阻塞性肺疾病患者运动耐力和生活质量影响的meta分析[J].医学新知,2025,35(2):200-210.
[7] 梁振宇,王凤燕,陈荣昌.慢性阻塞性肺疾病诊治指南(2021年修订版)的重要更新解读及展望[J].国际呼吸杂志,2021,41(19):1457-1461.
[8] 刘青建,彭松灏,陆必波,等.线上线下相结合的揿针联合呼吸吐纳功法对社区COPD稳定期患者肺功能、血气指标以及生存质量的影响[J].四川中医,2023,41(7):219-222.
[9] 尹欣,吴毅凌,侯珊珊,等.上海市松江区40岁及以上社区女性居民生殖健康因素与肺功能及慢性阻塞性肺疾病的关联[J].复旦学报(医学版),2024,51(6):882-889.
[10] 张亚敏,温书景,霍瑛辉.改良版Padua评分在COPD患者实施VTE个体化防护方案中的应用效果[J].医学临床研究,2025,42(5):765-768.
[11] 秦宏花,郭海嬿,李海峰,等.布地格福吸入气雾剂治疗慢性阻塞性肺疾病安全性的Meta分析[J].药物流行病学杂志,2025,34(7):771-784.
[12] 李强,赵凤德,王瑞瑞,等. 布地格福吸入气雾剂联合白葡奈氏菌片维持治疗中重度慢性阻塞性肺疾病稳定期患者的临床观察[J].中国药房,2024,35(19):2391-2396.
[13] 崔凌燕,柳光春.间断负荷训练在稳定期COPD患者运动耐力恢复中的应用效果[J].医学临床研究,2024,41(7):987-990.
[14] 向敏敏.标准化呼吸训练对COPD患者生活质量的影响[J].中国标准化,2025,68(2):285-288. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(4): 693-696. |
|
|
|
|
2026, Vol. 43 
